Supernus (SUPN) Q1 2026 earnings review
Growth Portfolio Surges, Aided by a $20M Milestone
Supernus delivered a strong Q1 2026, posting 39% YoY revenue growth to $207.7 million. However, the headline number was significantly flattered by a $20.0 million one-time licensing milestone from Shionogi. Under the hood, the core business transition is accelerating: the 'four growth products' (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) generated $149.1 million, up 56% YoY. Most crucially, ONAPGO supply constraints that plagued late 2025 appear resolved, with new patient initiations resuming in February. Despite the top-line beat, GAAP profitability remains elusive due to heavy acquisition amortization and clinical milestone payouts, resulting in a -$2.3 million net loss. Management reiterated FY26 guidance, signaling confidence in the current trajectory.
🐂 Bull Case
After a supply-constrained 2025, ONAPGO is fully re-launched. New patient initiations resumed in February 2026, generating $8.4M in the quarter. With 2,200 enrollment forms processed since launch, the pent-up demand is converting into revenue.
The Sage Therapeutics acquisition is paying off rapidly. ZURZUVAE collaboration revenue hit $27.6M in Q1, with underlying Biogen-reported U.S. sales jumping ~100% YoY and prescriptions growing 82%. This represents a high-margin, accelerating revenue stream.
🐻 Bear Case
Despite a $20M one-time milestone, the company still posted a GAAP operating loss of $8.3M. Heavy intangible amortization ($25.6M) and rising clinical R&D expenses ($10.0M to Biscayne security holders) continue to drag down the bottom line.
While ONAPGO is supplying patients again, Supernus is reliant on a single supplier for a guided $45M-$70M in FY26 demand. A submission for a second supplier is planned for Q3 2026, but FDA approval isn't expected until mid-2027.
⚖️ Verdict: 🟢
Bullish. The strategic pivot away from legacy products is substantially complete. The four growth pillars are firing on all cylinders, and the resolution of ONAPGO's supply bottleneck removes the largest overhang from 2025.
Key Themes
The Four Pillars are Accelerating
The portfolio transition is a clear success. Combined revenues from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO reached $149.1 million, accelerating 56% YoY. Qelbree alone grew 20% to $77.9 million, driven by a 19% increase in prescriptions and an all-time high of ~43,000 prescribers. These four assets are more than offsetting the expected declines in legacy products.
ONAPGO Supply Constraints Resolved
The most critical operational update is that ONAPGO new patient initiations resumed in February 2026. The product generated $8.4 million in Q1—a highly encouraging number given it only had two full months of unconstrained operation. The 2,200 enrollment forms submitted since launch point to strong underlying demand.
Legacy Product Erosion
Decelerating. Trokendi XR and Oxtellar XR continue their structural decline, falling 26% and 27% YoY, respectively, to a combined $16.9 million. While expected, this creates a persistent mechanical drag on top-line growth that requires the new assets to out-grow the decay.
GAAP Margins Masked by Milestone and R&D Payments
Despite revenue surging 39%, the company posted an $8.3M operating loss. A deeper look reveals structural margin pressures: $25.6M in intangible amortization (up from $19.8M YoY due to the Sage acquisition) and a specific $10.0M clinical program payout to former Biscayne security holders for SPN-817. SG&A also increased due to the Biogen collaboration.
Pipeline: SPN-820 and SPN-817 Advancing
R&D investments remain stable. The Phase 2b study for SPN-817 (epilepsy) is ongoing with ~258 patients targeted. SPN-820 (depression) is proceeding with its multi-center Phase 2b trial testing an intermittent (twice-weekly) 2400mg dose. The novel stimulant SPN-443 is on track to initiate Phase 1 trials in H2 2026. Data readouts are not expected until at least 2027, making this a long-term catalyst rather than a near-term driver.
Other KPIs
Stable. Up from $25.9M in Q1 2025. This non-GAAP metric strips out the heavy $25.6M intangible amortization and $8.5M in share-based compensation, providing a clearer view of core cash-generation capacity of the commercial portfolio.
Accelerating. Up from $308.7M at year-end 2025. The $75.5M sequential increase was driven by strong operating cash flow and the $20.0M Shionogi commercial milestone. With zero debt, Supernus has fully reloaded its balance sheet post-Sage acquisition, opening the door for further M&A.
A massive addition to the P&L compared to Q1 2025 ($0). U.S. sales reported by partner Biogen grew ~100% YoY, proving that the postpartum depression market is highly receptive to the oral therapy. The 82% Rx growth validates the $73M integration investment Supernus made in 2025.
Guidance
Accelerating. The midpoint of $855M implies an 18.9% growth over FY25's $719M record. This outlook assumes the four growth products easily compensate for the continued bleed in legacy drugs.
Accelerating. Implies massive growth from the $17.3M generated in the launch year of FY25. With Q1 coming in at $8.4M, the company needs to average ~$16M per quarter for the rest of the year to hit the midpoint, requiring steady patient initiation and strict supply chain execution.
Stable. The $155M midpoint is roughly in line with FY25's actual $158.7M, implying that while revenue is growing rapidly, the flow-through to adjusted earnings is muted by the guided $620-$650M spend in combined R&D and SG&A to support ZURZUVAE and pipeline expansion.
Key Questions
ONAPGO Second Supplier Readiness
You are guiding to $45-$70M in ONAPGO sales relying entirely on the current supplier until mid-2027. If demand spikes to the upper end of that range, what specific assurances do you have that the current supplier won't trigger another pause?
M&A Strategy and Capacity
With the cash balance recovering to $384M, is the primary focus for M&A still commercial-stage assets, and are you actively looking at expanding further into the Women's Health vertical you acquired via Sage?
Qelbree Gross-to-Net Dynamics
Qelbree saw strong 20% net sales growth on 19% Rx growth. Can you discuss the gross-to-net pricing stability in Q1 and your expectations for the remainder of the year?